Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3526318 for Diabetic Peripheral Neuropathic Pain
NCT05177094Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing LY3526318 with Placebo (2 arms). Primary endpoint: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale at 8 weeks. Started Jan 2022; status: completed.
02
Drugs
LY3526318
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT05177094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177094.